- Academic Editor
-
-
-
†These authors contributed equally.
Background: Lung cancer is one of the major cause of death globally.
Crizotinib is a first-line drug used in treating non-small-cell lung cancer
(NSCLC). However, the pathophysiological mechanisms underlying its cardiotoxicity
are unknown. This study investigated the mechanisms of crizotinib-induced
cardiotoxicity and explored whether this toxicity can be prevented by the
angiotensin receptor/neprilysin inhibitor sacubitril/valsartan. Methods:
Male C57BL/6 mice were randomly divided into three groups: control, crizotinib
(40 mg